Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flortaucipir F 18 - Avid Radiopharmaceuticals

Drug Profile

Flortaucipir F 18 - Avid Radiopharmaceuticals

Alternative Names: 18F-AV-1451; [18F]-T-807; [3H]AV 1451; [F-18]T807; [F18]AV1451; Fluorine 18 AV 1451; LY3191748; T807; Tauvid

Latest Information Update: 17 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Siemens Medical Solutions
  • Developer Avid Radiopharmaceuticals; Northwestern University
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Alzheimer's disease
  • Phase II Brain injuries; Cognition disorders; Dementia; Depressive disorders; Neurodegenerative disorders; Progressive supranuclear palsy
  • No development reported Aphasia; Mild cognitive impairment

Most Recent Events

  • 07 Sep 2020 Avid Radiopharmaceuticals terminates a phase II trial for Alzheimer's disease (Diagnosis) in USA (NCT02051764)
  • 28 Jul 2020 No recent reports of development identified for phase-I development in Mild-cognitive-impairment(Diagnosis, In the elderly, In adults) in USA (IV, Injection)
  • 28 May 2020 Registered for Alzheimer's disease (Diagnosis, In the elderly, In adults) in USA (IV)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top